You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA310
  • Published:  23 April 2014
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Lung cancer (non small cell, EGFR mutation positive) - afatinib: draft scope - (pre referral)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: draft scope - (pre referral) Lung cancer (non small cell, EGFR mutation positive) - afatinib: draft scope - (pre referral)
03 April 2013
(109.13 Kb 31 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 03 April 2013

Back to top